13 November 2019
Emerging infectious diseases continue to be a major concern because of their potential consequences - this session will outline what they are, give some examples and explain why they continue to emerge.
|Presenter:||Professor Iain Gosbell, National Donor and Product Safety Specialist, Australian Red Cross Blood Service.|
This session will be prerecorded and released on 14 August 2019
Granulocytes may be beneficial in selected patients. This session will discuss the indications, pitfalls, benefits and controversies surrounding granulocyte transfusions.
|Presenter:||Dr Kobie (Jacoba) von Wielligh, Transfusion Medicine Specialist, Pathology Services, Australian Red Cross Blood Service.|
13 March 2019 01:30pm - 02:30pm Australia/Sydney
This session will discuss the impact of red cell transfusion in improving patient functional status in chronic disease.
|Presenter:||Dr Philip Crispin, Consultant Haematologist, Canberra Hospital.|
Genomic profiling of red cell and platelet antigens allows for more precise transfusion therapy and is set to change transfusion practice. The impact of genomics on transfusion will be discussed.
|Presenter:||Dr Anastazia Keegan, Transfusion Medicine Specialist, Australian Red Cross Blood Service.|
11 July 2018 Topic will be prerecorded and made available at 1:30PM AEST
Presenter: Professor Iain Gosbell, National Donor and Product Safety Specialist
Emerging infectious diseases have been of major concern to humanity because of their consequences for our survival, even into the 21st century. The webinar will outline what emerging infectious diseases are, give some examples, and explain why they continue to emerge. A minor part of this can be attributed to climate change, but the biggest drivers are overpopulation and increased travel. There are many other drivers as well, so we can expect there to be an ongoing problem with these conditions. Some of these emerging infectious diseases pose a problem for the safety of the blood supply for transfusion, and how it is identified and mitigated is explained, giving three examples of emerging or re-emerging diseases: Zika virus, hepatitus E and hepatitus A.
13 June 2018 01:30 - 02:30pm - Australia/Sydney
The news in "artificial blood” is that two research groups have transformed adult cells into stem cells that can regenerate both themselves and all the cellular components of blood. This development has been described as "the holy grail”, and offers a potential treatment for those who need bone marrow transplants and can't find appropriate donors. This is a significant milestone in regenerative medicine, and if taken to its logical conclusion, may reduce or eliminate the need for bone marrow transplants as well as red cell and platelet donations. However, these reports are a long way (many years) from clinical application in humans at present. The current state of play is presented.
|Presenter:||Dr Rebecca Griffiths, Senior Post Doctoral Scientist - Stem Cell Ageing and Regenerative Engineering Australian Institute for Bioengineering and Nanotechnology, The University of Queensland.|
18 April 2018 01:30 - 02:30pm - Australia/Sydney
Trauma is the leading cause of death worldwide in individual's aged 18-39 with data from the WHO suggesting that worldwide almost 6 million deaths every year are directly attributable to trauma. Despite advances in trauma management, a significant proportion of these deaths are still due to haemorrhage. Death can occur early as a result of uncontrollable haemorrhage; in patients where surgical haemorrhage control is achieved subsequent morbidity and mortality can be attributed to effects of massive haemorrhage and large volume blood product transfusion. This session will provide an update for the Feisty Study - An Australian multi-centre randomised, controlled trial studying the effects of rapid fibrinogen replacement in severely bleeding trauma patients.
|Presenter:||Dr James Winearls, Consultant Intensivist, Gold Coast University Hospital, (Chief Investigator).|
14 February 2018 01:30pm - 02:30pm Australia/Sydney
This session will report the results for the TRANSFUSE-RCT, the multi-centre, randomised, controlled trial, testing the effect of the freshest available red blood cell (RBC) unit compared to standard practice, on mortality in critically ill patients who require RBC transfusion.
|Presenter:||Dr Zoe McQuilten, Consultant Haematologist, Senior Research Fellow, Monash University.|
25 October 2017 01:30 - 02:00pm - Australia/Sydney
This session covers what DIC is, its causes and occurrences along with the pathophysiology and treatment.
Dr Oi-Lin Lee is a Transfusion Medicine Specialist at the Blood Service.
26 July 2017 01:30pm - 02:00pm - Australia/Sydney
This session provides an overview of exchange transfusions and how to transfuse a neonate.
Dr Ben Saxon is a Transfusion Specialist in the Transfusion Policy and Education Department at the Blood Service.
12 July 2017 12:30pm - 01:30pm - Australia/Sydney
Hepatitis C is transmissible by transfusion. The Blood Service has tested all donated blood and blood product for hepatitis C virus RNA and antibodies since 1990. Another viral infectious disease, Zika virus, made international news headlines in 2016 due to its largest ever documented outbreak in several countries. Zika virus has also been shown to be transmissible by transfusion. Evidence that Zika is occasionally responsible for severe outcomes including birth defects and Guillain-Barré Syndrome is now compelling. This session provides an overview of Hepatitis C and Zika virus, their transmission, management and related concerns about safety of blood transfusion.
|Presenter:||Dr George Kotsiou, National Donor and Product Safety Specialist, Blood Service.|
17 May 2017 01:30pm - 02:00pm - Australia/Sydney
This session explores the assessment of a patient's clinical status before deciding on a transfusion and discuss some of the practicalities in making this assessment.
Dr Philip Crispin is a clinical haematologist at Canberra Hospital and NSW Southern Area Hospital Network.
15 March 2017 01:30 - 02:00pm - Australia/Sydney
This session explores the medical management for a patient who refuses a transfusion.
Professor Bernd Froessler is an Anaesthetist at the Lyell McEwin Hospital.
22 June 2016 01:30pm - 02:00pm - Australia/Sydney
This session explores the mechanism of coagulation and transfusion support (including cryoprecipitate, platelets and prothrombinex) that may be required to stop bleeding.
Dr Kobie Von Wielligh is a Haematologist and Transfusion Medicine Specialist at the Blood Service.
In this presentation, recorded at Transfusion Update 2016, Dr Roger Dodd explores aspects of blood safety over the past 20 years. He focuses on infections transmitted by insects, touching on West Nile virus, dengue, chikungunya, Ross River virus, Zika, Chagas disease, Babesia, and identifies continuing efforts to recognise emerging infections in order to protect the blood supply.
14 October 2020 01:30pm - 02:30pm Australia/Sydney
For Lifeblood, providing a safe and secure blood supply is paramount, however, this must balance the effective use of healthcare resources. A key principle is keeping risks as low as reasonably achievable and risk tolerability is a vital element in achieving this. The Alliance of Blood Operators (ABO) Risk Based Decision Making (RBDM) Framework was developed as a structured and systematic process to ensure emerging blood safety risks take into account not only blood safety but operational, economic and societal factors to ensure. This presentation will go through recent examples of how the RBDM has been used by Lifeblood and highlight current risk tolerability for transfusion-transmitted infections.
|Presenter:||Dr Veronica Hoad, Public Health Physician, Clinical Services and Research, Australian Red Cross Lifeblood.|